Indication
Clinical Stage III Cutaneous Melanoma AJCC v8
29 clinical trials
29 products
18 drugs
Clinical trial
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk MelanomaStatus: Active (not recruiting), Estimated PCD: 2022-09-01
Product
PembrolizumabClinical trial
A Phase II Study to Evaluate the Safety and Efficacy of Rigosertib (ON 01910) Plus Pembrolizumab in Patients With Metastatic Melanoma Refractory to Immune Checkpoint BlockadeStatus: Recruiting, Estimated PCD: 2028-05-01
Product
RigosertibClinical trial
PNV21-001: A Phase I Study of a Personalized Multi-Peptide Neo-Antigen Vaccine in Breast Cancer and PD1/PD-L1 Inhibitor-Refractory MelanomaStatus: Recruiting, Estimated PCD: 2024-11-01
Product
Neoantigen Peptide VaccineClinical trial
Phase I Trial to Evaluate the Safety and Efficacy of Intratumoral and Intravenous Injection of Vesicular Stomatitis Virus Expressing Human Interferon Beta and Tyrosinase Related Protein 1 (VSV-IFNb-TYRP1) in Patients With Metastatic Ocular Melanoma and Previously Treated Patients With Unresectable Stage III/IV Cutaneous MelanomaStatus: Active (not recruiting), Estimated PCD: 2027-01-20
Product
Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta and Tyrosinase Related Protein 1Product
NivolumabProduct
Poly ICLCClinical trial
Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Participants With Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot StudyStatus: Recruiting, Estimated PCD: 2024-09-01
Product
CabozantinibClinical trial
A Phase 1/2 Study of Nivolumab and Ipilimumab in Combination With Sirolimus and Prednisone in Kidney Transplant Recipients With Selected Unresectable or Metastatic Cutaneous CancersStatus: Recruiting, Estimated PCD: 2027-01-31
Product
IpilimumabClinical trial
A Phase I Pilot Study of Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab in Advanced Solid Tumors (PNeoVCA)Status: Recruiting, Estimated PCD: 2025-02-24
Drug
cyclophosphamideProduct
PrednisoneDrug
sirolimusClinical trial
An Open-label, Single-Center, Phase 1b/2 Study to Evaluate the Safety of Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Malignancies After Progression on PD-1 or PD-L1 Targeted AntibodiesStatus: Recruiting, Estimated PCD: 2025-06-01
Drug
AtezolizumabProduct
AvelumabProduct
DurvalumabProduct
PlinabulinClinical trial
Phase 1 Study of the Administration of Ipilimumab Intra-Lymphatically Using the Sofusa® DoseConnect™ DEVICE With Nivolumab Administered IV in Patients With Metastatic MelanomaStatus: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
Phase I Study of MK-3475 (Pembrolizumab) in Patients With Human Immunodeficiency Virus (HIV) and Relapsed/Refractory or Disseminated Malignant NeoplasmStatus: Active (not recruiting), Estimated PCD: 2023-10-04
Product
Antiretroviral TherapyClinical trial
Phase 1 Study of the Administration of STI-3031 (Anti-PDL1) Intra-Lymphatically Using the Sofusa® DoseConnect™ DEVICE in Patients With In-Transit Melanoma (Sofusa-2)Status: Active (not recruiting), Estimated PCD: 2026-01-01
Clinical trial
A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic MelanomaStatus: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
Neoadjuvant Therapy for Patients With High Risk Stage III Melanoma: A Pilot Clinical TrialStatus: Recruiting, Estimated PCD: 2025-06-29
Product
CobimetinibDrug
TiragolumabClinical trial
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III TrialStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Product
DabrafenibDrug
T-VECProduct
TrametinibClinical trial
Pilot Trial of Nivolumab Plus Cabozantinib for Advanced Solid Tumors in Patients With HIV InfectionStatus: Active (not recruiting), Estimated PCD: 2025-11-02
Clinical trial
A Phase 2 Study of Combination Treatment of Binimetinib and Nivolumab for Advanced V600BRAF Wildtype Melanoma With Innate Anti-PD-1 ResistanceStatus: Recruiting, Estimated PCD: 2024-06-01
Product
BinimetinibProduct
VemurafenibClinical trial
A Phase II Randomized Study of Nivolumab (NSC-748726) With Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 AgentStatus: Active (not recruiting), Estimated PCD: 2023-09-19
Clinical trial
Phase II Randomized Study of Neoadjuvant Pembrolizumab Alone or in Combination With CMP-001 in Patients With Operable Melanoma: Efficacy and Biomarker StudyStatus: , Estimated PCD: 2024-12-31
Drug
mFOLFOX6Clinical trial
Phase I Trial of Sonidegib and Pembrolizumab in Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2024-07-01
Product
SonidegibClinical trial
A Single-Center Phase I Dose Escalation/Response Trial to Evaluate Safety, Tolerability, and Anti-Tumor Efficacy of Intra-Arterial CBL0137 for Patients With Advanced Extremity Melanoma or SarcomaStatus: Terminated, Estimated PCD: 2024-01-16
Product
CBL0137Clinical trial
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced MalignanciesStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Drug
UTD1Drug
AN0025Drug
doxorubicinDrug
fluorouracilProduct
IrinotecanProduct
OlaparibClinical trial
The Safety and Efficacy of Endostar Combined With Toripalimab as Postoperative Adjuvant Therapy for Resectable Stage III-Oligometastatic Stage IV Cutaneous Melanoma: A Prospective, Single-arm, Open-label, Phase II Clinical StudyStatus: Recruiting, Estimated PCD: 2024-08-01
Drug
EndostarDrug
PD-1 antibodyClinical trial
Pilot Single-Arm, Pragmatic Trial of In-Home Versus In-Clinic Subcutaneous Nivolumab Administration Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) ProgramStatus: Recruiting, Estimated PCD: 2026-12-31
Drug
FOLFOXIRIProduct
PemetrexedDrug
SelinexorClinical trial
Immune Checkpoint Blockade for Kidney Transplant Recipients With Selected Unresectable or Metastatic CancersStatus: Active (not recruiting), Estimated PCD: 2022-10-11
Drug
LurbinectedinProduct
TopotecanDrug
R-CHOPDrug
VarlilumabClinical trial
A Phase II Study of Biomarker Driven Early Discontinuation of Anti-PD-1 Therapy in Patients With Advanced Melanoma (PET-Stop)Status: Recruiting, Estimated PCD: 2026-08-29
Clinical trial
Phase I/II Study of Dabrafenib, Trametinib, and Navitoclax in BRAF Mutant Melanoma (Phase I and II) and Other Solid Tumors (Phase I Only)Status: Active (not recruiting), Estimated PCD: 2024-12-31
Product
NavitoclaxClinical trial
A Phase II Study to Assess the Safety and Efficacy of Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial CarcinomaStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
Single Arm Study to Assess the Immune Effects of Fermented Wheat Germ (FWG) Nutritional Supplementation in Patients With Advanced Malignancies Being Treated With Standard of Care Checkpoint Inhibitor-Based TherapyStatus: Recruiting, Estimated PCD: 2025-06-02
Product
Fermented Wheat Germ ExtractDrug
TocilizumabClinical trial
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected MelanomaStatus: Active (not recruiting), Estimated PCD: 2023-09-15